Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C

95 percent of patients infected with genotype 3 (GT3) chronic hepatitis C virus (HCV), without cirrhosis and who are new to treatment, achieved SVR(12) with 8 weeks of treatment(1) Together with previously reported data, these study results support the ... Biopharmaceuticals AbbVie, glecaprevir, pibrentasvir, hepatitis C, ENDURANCE-3
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news